Bryant David Lim insider trades: Prelude Therapeutics (PRLD) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Bryant reports to the SEC
Open-market buys and sales
7 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Dec 19, 2024 | PRLD | ↑ Buy | 25,000 | $0.91 | $23K | Direct | Dec 20, 2024 (1d) |
| May 24, 2023 | PRLD | ↑ Buy | 2,400 | $5.39 | $13K | Direct | May 25, 2023 (1d) |
| Mar 25, 2021 | IDRA | ↓ Sell | 7,630 | $1.36 | $10K | Direct | Mar 29, 2021 (4d) |
| Jan 12, 2021 | IDRA | ↓ Sell | 1,711 | $4.21 | $7K | Direct | Jan 12, 2021 (0d) |
| Jan 5, 2021 | IDRA | ↓ Sell | 1,465 | $3.91 | $6K | Direct | Jan 11, 2021 (6d) |
| Jan 7, 2020 | IDRA | ↓ Sell | 1,603 | $1.78 | $3K | Direct | Jan 10, 2020 (3d) |
| Dec 21, 2018 | IDRA | ↑ Buy | 4,000 | $3.05 | $12K | Direct | Dec 26, 2018 (5d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Bryant David Lim's insider trades
Bryant David Lim is CLO, CFO, Corp Sec. at Prelude Therapeutics (PRLD). Since Dec 21, 2018, Bryant has reported 3 open-market purchases worth $48K and 4 sales worth $26K on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include grants and awards (17 filings), shares withheld for taxes (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every PRLD insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.